Myovant Sciences is a brand dedicated to improving the lives of millions through purpose-driven science, empowering medicines, and transformative advocacy. They focus on developing innovative medicines for women with uterine fibroids and endometriosis, as well as men with prostate cancer. With an estimated 19 million women in the U.

S. Additionally, they aim to provide solutions for the approximately 3 million men in the U. S.

Through their pipeline of medicines, such as the Relugolix Combination Tablet and MVT-602, Myovant Sciences is committed to redefining care. They also engage in advocacy efforts to fight stigma, raise awareness, and empower people with information. Discover more about their impactful work on their website, through their social media channels, and by joining their dedicated team